Program by Day

« Back

Print this page

	Personalized Program The Personalized Program enables you to compile an individual program with events and contributions of your interest. Therefore, it can be used very well to plan your actual congress visit at an early point of time. Please log in to use the Personalized Program.	» Login » Identification » Help

« previous day	Thursday, 2. July 2009

No.	S-76 - Symposium
Time:	08.00-09.30
Room:	Blue Amphitheatre
Topic:	Brain Function
Track:	1 Basic
Session title:	Neuroanatomical aspects of prepulse inhibition in schizophrenia: Animal models and human psychoses
	Rainer Wolf, Germany	Chair
	Georg Juckel, Germany	Co-Chair

001	Reduction of prepulse inhibition (PPI) after neonatal excitotoxic lesion of the ventral thalamus in pubertal and adult rats
	Rainer Wolf, Germany	Speaker
002	Perinatal hypoxia as probable animal model of schizophrenia
	Andrea Schmitt, Germany	Speaker
003	Pharmacological studies of prepulse inhibition models of schizophrenia
	Maarten van den Buuse, Australia	Speaker
004	Brain imaging (fMRI) studies of startle gating deficits in schizophrenia patients treated with typical or atypical antipsychotics
	Veena Kumari, United Kingdom	Speaker

No.	S-77 - Symposium
Time:	08.00-09.30
Room:	Salle Maillot
Topic:	Other
Track:	3 Interface
Session title:	Strengths and weaknesses of evidence-based medicine (EBM) in general and its particular role in psychiatry
	Michael Davidson, Israel	Chair

No.	S-78 - Symposium
Time:	08.00-09.30
Room:	Room 352AB
Topic:	Affective Disorders (Unipolar)
Track:	2 Clinical
Session title:	The emerging role of TMS in the treatment of psychiatric disorders
	Philip Janicak, USA	Chair
	Abraham Zangen, Israel	Co-Chair

001	Transcranial magnetic stimulation of deep brain regions: An overview and ongoing studies in psychiatric patients and healthy subjects
	Abraham Zangen, Israel	Speaker
002	Predictive factors and biomarkers for TMS in depression
	Jeffrey Rado, USA	Speaker
003	TMS for other neuropsychiatric disorders
	Eman Khedr, Egypt	Speaker
004	Efficacy of TMS for depression and review of large sham-controlled trial
	Philip Janicak, USA	Speaker

No.	S-79 - Symposium
Time:	08.00-09.30
Room:	Room 252B
Topic:	Neuroimaging
Track:	1 Basic
Session title:	Paralimbic determinations and developmental psychiatry
	Jean-Luc Martinot, France	Chair
	Philip McGuire, France	Co-Chair

001	Cortex gyrification in schizophrenia and bipolar patients
	Arnaud Cachia, France	Speaker
002	Pharmaceutical challenges and at-risk subjects
	Philip McGuire, France	Speaker
003	Addiction imaging implication for prevention
	Jean-Luc Martinot, France	Speaker
004	Cognitive reserve Alzheimer's disease and temporal
	David Bartres'Faz, Spain	Speaker

No.	S-80 - Symposium
Time:	08.00-09.30
Room:	Room 241
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	The neural bases of hallucinations in schizophrenia: Recent advances in research
	Kevin Spencer, USA	Chair
	Daniel Mathalon, USA	Co-Chair

001	Hallucination symptoms and oscillatory brain dynamics in schizophrenia
	Kevin Spencer, USA	Speaker
002	Corollary discharge dysfunction in Schizophrenia
	Judith Ford, USA	Speaker
003	Relation beween functional and structural cerebral changes in auditory verbal hallucinations
	Thomas Dierks, Switzerland	Speaker
004	Probing the pathophysiology of auditory/verbal hallucinations by combining fMRI and rTMS
	Ralph Hoffman, USA	Speaker

No.	FC-31 - Free Communications
Time:	08.00-09.30
Room:	Room 351
Topic:	Childhood Adolescent Disorder
Session title:	Childhood & Adolescent Disorders II
	Pierre Thomas, France	Chair
	Martin Hatzinger, Switzerland	Co-Chair

001	A month and 5-years follow-up study of postraumatic stress disorder in children
	Ruby Castilla-Puentes, USA	Speaker
002	The influence of word meaning on central auditory processing in SLI children as indexed by Mismatch Negativity
	Sung-Eun Lee, Germany	Speaker
003	Examination of executive dysfunction as an endophenotype for attention-deficit/ hyperactivity disorder in an ethnic Chinese population
	Susan Shur-Fen Gau, Taiwan	Speaker
004	Deep brain stimulation for severe head-banging, self-injury, and aggression in adolescent refractory Tourettes
	Shannon Morton, Australia	Speaker
005	Hyperactivity-inattention symptoms in childhood and later academic achievement: The gazel youth study
	Cedric Galera, France	Speaker
006	Differences in Hypothalamic-Pituitary-Adrenal axis functioning among children with ADHD predominiantly inattentive and combined types
	Dirk van West, Belgium	Speaker

No.	FC-32 - Free Communications
Time:	08.00-09.30
Room:	Room 242A
Topic:	Psychopharmacology
Session title:	Psychopharmacology V
	Joseph Zohar, Israel	Chair
	Liliana Rendon, Paraguay	Co-Chair

001	Pisa Syndrome induced by atypical antipsychotics
	Susana Mendes, Portugal	Speaker
002	Randomized placebo controlled trials of n-acetyl cysteine as adjunct therapy for schizophrenia and bipolar disorder
	Olivia Dean, Australia	Speaker
003	Prevalence of lower-than-expected plasma levels in medicated patients presenting for acute inpatient treatment
	Christian Geretsegger, Austria	Speaker
004	The anxiolytic etifoxine reduces the physical signs and anxiogenic effects of ethanol withdrawal in mice
	Marc Verleye, France	Speaker
005	Effects of sertindole on MK-801 induced impairment of memory in radial arm maze test
	Ipek Komsuoglu Celikyurt, Turkey	Speaker
006	Early perturbation in feeding behavior and energy homeostasis in olanzapine-treated rats
	Renaud de Beaurepaire, France	Speaker

No.	FC-33 - Free Communications
Time:	08.00-09.30
Room:	Room 242B
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders VIII
	Carlo Altamura, Italy	Chair
	N N	Co-Chair

001	Enhanced synaptic plasticity at hippocampal output synapses in the MK-801 model of psychosis
	Julia Bartsch, Germany	Speaker
002	Temporal processing dysfunction in medicated and unmedicated patients with schizophrenia
	Chara Malapani, USA	Speaker
003	Schizophrenia, serotonin, gender and age of onset: An association study in a Spanish sample
	Javier Gilabert Juan, Spain	Speaker
004	Cortical gyrification in twins discordant for schizophrenia
	Raka Maitra, Germany	Speaker
005	Silenced and overexpressed genes: Incorporating epigenetic factors in the Etio-Pathology of schizophrenia
	Zeinab Elbaz, USA	Speaker
006	Modelling thalamo-cortical circuits and auditory processing in schizophrenia
	Ralf Mueller, Germany	Speaker

No.	PL-05 - Plenary Lecture
Time:	09.45-10.30
Room:	Main Amphitheatre
Topic:	Neuroimaging
Session title:	Advancements in molecular (PET) imaging provide a cornerstone in future psychiatry research
	Birte Glenthoj, Denmark	Chair

001	Advancements in molecular (PET) imaging provide a cornerstone in future psychiatry research
	Lars Farde, Sweden	Speaker

No.	YS-05 - Young Scientists Award Session
Time:	09.45-10.30
Room:	Room 242A
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders II
	Olivier Blin, France	Chair
	Peter Riederer, Germany	Co-Chair

001	Spatial reference in schizophrenia
	Steffen Landgraf, Germany	Speaker
002	Schizophrenia: GSK-3ß and PLA2 dysregulation
	Augusto Vieira, Brazil	Speaker
003	Delusions in bipolar disorder: Similarities and differences with schizophrenia
	Susan Rossell, Australia	Speaker

No.	TG-09 - WFSBP Treatment Guidelines
Time:	11.00-12.30
Room:	Room 242A
Topic:	Anxiety
Session title:	Anxiety
	Robertas Bunevicius, Lithuania	Chair

	Joseph Zohar, Israel	Presenter
	Veronica Larach-Walters, Chile	Presenter

No.	SL-04 - Special Lecture
Time:	11.00-12.00
Room:	Blue Amphitheatre
Topic:	Affective Disorders (Unipolar)
Session title:	Depression and Mens Health - what s new? under the auspices of WFSBP and ISMH
	N N	Chair

001	Depression and Mens Health - what s new?
	Siegfried Meryn, Austria	Speaker

No.	D-09 - Debate
Time:	11.00-12.30
Room:	Room 351
Topic:	Psychotic Disorders
Session title:	Have we learnt anything of clinical relevance about schizophrenia over the last 50 years?
	Michael Trimble, United Kingdom	Chair

	Dan Rujescu, Germany	Proponent
	Florence Thibaut, France	Opponent

No.	W-12 - Workshop
Time:	11.00-12.30
Room:	Room 242B
Topic:	Affective Disorders (Unipolar)
Session title:	Is there still a place for unipolar depression?
	Andrea Lopez Mato, Argentina	Chair

001	Genetic differences between unipolar and bipolar depression
	Alejo Corrales, Argentina	Speaker
002	Clinical differences between unipolar and bipolar depression
	Jose Luis Ayuso Gutierrez, Spain	Speaker
003	Psychoneuroimmunoendocrinological differences between unipolar and bipolar depression
	Andrea Lopez Mato, Argentina	Speaker
004	Therapeutical differences between unipolar and bipolar depression
	Raquel Teresa Zamora-Cabral, Uruguay	Speaker

No.	S-81 - Symposium
Time:	11.00-12.30
Room:	Salle Maillot
Topic:	Brain Function
Track:	1 Basic
Session title:	Social cognition, social hormones and psychophathology
	Richard Ebstein, Israel	Chair
	Andreas Meyer-Lindenberg, Germany	Co-Chair

001	Neural and genetic mechanisms of human social behavior
	Andreas Meyer-Lindenberg, Germany	Speaker
002	Neuroanatomical bases of envy and gloating (schadenfreude)
	Simone Shamay-Tsoory, Israel	Speaker
003	The neuroendocrinology of social cognition
	Markus Heinrichs, Switzerland	Speaker
004	Genetics of social cognition
	Salomon Israel, Israel	Speaker

No.	S-82 - Symposium
Time:	11.00-12.30
Room:	Room 352AB
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	Auditory sensory gating in schizophrenia: Towards a better understanding of the genetical, neurophysiological, and neurochemical underpinnings
	Anke Brockhaus-Dumke, Germany	Chair
	Nash Boutros, USA	Co-Chair

001	Clinical correlates of N100 gating deficit in schizophrenia
	Nash Boutros, USA	Speaker
002	Role of the frontal cortex in both auditory and somatosensory habituation: An MEG study
	Susan Bowyer, USA	Speaker
003	The neurochemical basis of sensory gating in humans
	Maarten van den Buuse, Australia	Speaker
004	Time-frequency analysis of auditory sensory gating in first episode patients and subjects at risk
	Anke Brockhaus-Dumke, Germany	Speaker

No.	S-83 - Symposium
Time:	11.00-12.30
Room:	Room 252B
Topic:	Psychopharmacology
Track:	3 Interface
Session title:	Newer antipsychotic drugs: From neuroplasticity to neurotherapy
	Frank Tarazi, USA	Chair
	Marco Riva, Italy	Co-Chair

001	Neuroplasticity and signaling in the action of atypical antipsychotic drugs: Implications for functional recovery
	Marco Riva, Italy	Speaker
002	Receptor neuroplasticity of newer antipsychotic drugs
	Frank Tarazi, USA	Speaker
003	Serotonergic properties of antipsychotic drugs: Relevance to neuroplasticity
	Mohammed Shahid, United Kingdom	Speaker
004	Neuroplasticity as a target for innovative treatments. Effect of Clozapine in two animal models of schizophrenia.
	William T. O'Connor, Ireland	Speaker

No.	S-84 - Symposium
Time:	11.00-12.30
Room:	Room 241
Topic:	Childhood Adolescent Disorder
Track:	3 Interface
Session title:	Acute neuropsychiatric states in autism
	David Cohen, France	Chair
	Dirk Dhossche, USA	Co-Chair

001	Acute behavioral states in adolescent with autism hospitalized in a psychiatric intensive care unit
	David Cohen, France	Speaker
002	Catatonia in autism: Implications across the life span
	Dirk Dhossche, USA	Speaker
003	Self-injurious behavior in autism: Etiology, assessment and treatment
	Lea Elisabeth Wachtel, USA	Speaker
004	The role of epilepsy in children and adolescents with autism spectrum disorders
	Roberto Canitano, Italy	Speaker

No.	S-85 - Symposium
Time:	11.00-12.30
Room:	Room 251
Topic:	Neuroimaging
Track:	1 Basic
Session title:	New imaging evidence for illness progression throughout the course of schizophrenia
	Serge Mitelman, USA	Chair
	Monte Buchsbaum, USA	Co-Chair

001	Morphometric evidence of illness progression in schizophrenia
	René Kahn, Netherlands	Speaker
002	Diffusion tensor imaging tractography in schizophrenia
	Thomas Whitford, USA	Speaker
003	Structural brain changes during transition-to-illness phase in individuals at risk for schizophrenia
	Christos Pantelis, Australia	Speaker
004	A longitudinal study of white matter morphometry and organization in chronic schizophrenia
	Serge Mitelman, USA	Speaker

No.	FC-34 - Free Communications
Time:	12.30-14.00
Room:	Room 351
Topic:	Affective Disorders (Bipolar)
Session title:	Affective Disorders (Bipolar/Unipolar)
	Janusz Rybakowski, Poland	Chair
	Jose Luis Ayuso Gutierrez, Spain	Co-Chair

001	State-dependent elevation of interleukin-1 receptor antagonist (IL-1Ra) in bipolar mania
	Shang-Ying Tsai, Taiwan	Speaker
002	The use of background EEG activity to determine stimulus timing as a means of improving rTMS efficacy in the treatment of depression: A controlled comparison with standard techniques
	Joseph Lee, Australia	Speaker
003	Dopamine-beta-hydroxylase localization and outer membrane disruption of spherical acidophilic inclusions in depression
	Marietta R. Issidorides, Greece	Speaker
004	DNA methylation profiling of major depression
	Fatemeh Haghighi, USA	Speaker
005	Serotonin Transporter gene polymorphims and it correlation with depressive patients
	Patricia Chieri, Argentina	Speaker
006	Meta-analytic evidence for familial coaggregation of schizophrenia and bipolar disorder
	Jared Van Snellenberg, USA	Speaker

No.	FC-35 - Free Communications
Time:	12.30-14.00
Room:	Room 242A
Topic:	Addictive Disorders
Session title:	Addictive Disorders II
	Franck Bayle, France	Chair
	Saroja Krishnaswamy, Malaysia	Co-Chair

001	Blaming Parkinson's for addiction?
	Ingrid de Chazeron, France	Speaker
002	Treating social anxiety disorder effectively in patients with substance use disorders
	Christine Courbasson, Canada	Speaker
004	The intergenerational transmission of tobacco smoking - the role of parents’ long-term smoking trajectories
	Maria Melchior, France	Speaker
005	Automatized action schemata in nicotine dependence: Evidence from functional magnetic resonance imaging and a behavioral affordance paradigm
	Yavor Yalachkov, Germany	Speaker
006	Developmental changes in P300 amplitude and risk for substance use disorder
	Miguel Habeych, USA	Speaker

No.	FC-36 - Free Communications
Time:	12.30-14.00
Room:	Room 242B
Topic:	Brain Function
Session title:	Brain Function III
	Frank Padberg, Germany	Chair
	Prakash S. Masand, USA	Co-Chair

001	Sub-thalamic deep brain stimulation decreases metabolic activity in pre-frontal cortex in patients suffering from obsessive compulsive disorder
	Bruno Millet, France	Speaker
002	Effects of isolation-rearing on hippocampal cytoskeletal microtubular proteins, synaptic markers and behavioural phenotype in Sprague Dawley and Flinders Sensitive Line rats
	Massimiliano Bianchi, France	Speaker
003	Psychiatric disorder biomarker discovery - from differential expression to isoforms to pathways
	Chris Turck, Germany	Speaker
004	Determination of T-Cell subpopulations in CSF and peripheral blood in patients with affective and schizophrenic spectrum disorders to assess immunosurveillance and to apply as a diagnostic approach
	Karl Bechter, Germany	Speaker
005	A cytokine model of cognitive function
	Bernhard Baune, Australia	Speaker
006	Repetitive Transcranial Magnetic Stimulation (rTMS) in treatment of resistant obsessive-compulsive disorder
	Carlos Mansur, Brazil	Speaker

No.	P-42 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Affective Disorders (Bipolar)
Session title:	Affective Disorders (Bipolar) II
	Rainer Wolf, Germany	Chair

001	Factors associated with spatial working memory function in euthymic bipolar patients
	Aleksandra Suwalska, Poland	Presenter
002	Serum Progesterone in males during euthymic phase of Bipolar Disorder - subtype differences
	Anette Johansson, Sweden	Presenter
003	Quetiapine in the treatment of bipolar depression: Improvements in quality of life and functioning in four randomized, placebo - controlled trials
	Urban Gustafsson, Sweden	Presenter
004	The efficacy of quetiapine monotherapy in bipolar depression: Combined data from the BOLDER and EMBOLDEN studies
	Urban Gustafsson, Sweden	Presenter
005	The efficacy of quetiapine monotherapy in bipolar II depression: Combined data from the BOLDER and EMBOLDEN studies
	Urban Gustafsson, Sweden	Presenter
006	Effect of Quetiapine on the subjective estimates of sleep in the 8 weeks treatment of acute bipolar depression
	Bo-Hyun Yoon, Korea, Republic of	Presenter
007	Preclinical characterization of antidepressant effect of norquetiapine: Role of the norepinephrine transporter in preclinical depression models
	Dan Widzowski, USA	Presenter
008	Association study of brain-derived neurotrophic factor (BDNF) gene and bipolar disorder in Korea
	Duk-In Jon, Korea, Republic of	Presenter
009	Nutritional, metabolic and endocrine disorders in patients with bipolar disorder: A systematic review
	Julio Bobes, Spain	Presenter
010	The clinical approach to bipolar disorder diagnosis
	Giuseppe Tavormina, Italy	Presenter
012	French validation of the BAC-A (brief assessment of cognition in affective disorders): A pilot study
	Marie-Cecile Bralet, France	Presenter
013	Bipolarity in adolescent populations
	Nicolas Zdanowicz, Belgium	Presenter
014	Asenapine efficacy in patient subpopulations experiencing manic or mixed episodes of bipolar disorder: A pooled analysis
	Roger S. McIntyre, Canada	Presenter
015	A study to evaluate the efficacy, safety and tolerability of atipical antipcychotics in subjects with bipolar disorder Type 1
	Roxana Chirita, Romania	Presenter
016	Cannabis use and bipolar disorder: Search for association and causality through a review of literature
	Sami Richa, Lebanon	Presenter
017	Family history, obstetric complications and age of onset in bipolar patients
	Selim El-Badri, New Zealand	Presenter
018	Mixed states with or without psychotic symptoms: 24-month outcomes of the European Cohort Emblem
	Michael Lukasiewicz, France	Presenter
019	Spanish consensus on physical health in patients with bipolar disorder
	Eduard Vieta, Spain	Presenter

No.	P-43 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Affective Disorders (Unipolar)
Session title:	Affective Disorders (Unipolar) IV
	Michael Bauer, Germany	Chair

001	Epidemiology of female obesity and depression in different age groups
	Alina Matynova, Russia	Presenter
002	Neurotic hostility explains the association between depressive mood and mortality: Evidence from the French GAZEL cohort study
	Cedric Lemogne, France	Presenter
004	Patients suffering from major depressive disorder show an altered interaction between cardiac vagal influence and delta sleep EEG
	Fabrice Jurysta, Belgium	Presenter
005	Seasonal distribution of mania in a psychiatric emergency room
	Fernando Volpe, Brazil	Presenter
006	Premorbid sleep, cognitive and activity circadian profile in depressed patients
	Giuseppe Bersani, Italy	Presenter
007	Prevalence of sleep disorders among patients with anxiety and depressive symptoms
	Jozef Dragasek, Slovak Republic	Presenter
008	Primary and Secondary Interferon-Alpha induced depression: Cytokine levels and depression ratings
	Kimberley Smith, Ireland	Presenter
009	Comorbidity between major depression and arthritis
	Lilijana Oruc, Bosnia and Herzegovina	Presenter
010	Decreased aldosterone and renin in suicide attempters with major depressive disorder
	Ludvig Hallberg, Sweden	Presenter
011	Health - related quality of life in depression patients
	Margarita Staniute, Lithuania	Presenter
012	The effect of saffron extract on behavioral changes and depression in male rates
	Mostafa Hamdieh, Iran	Presenter
013	Increased plasma levels of novel monoamine oxidase, renalase, in patients with major depressive disorder and panic disorder
	Nina Eikelis, Australia	Presenter
014	Tryptophan and Kynurenine metabolism abnormalities in an experimental model of major depressive disorder: The unpredictable chronic mild stress in mice
	Pascal Barone, France	Presenter
015	Depression, relationship and communication
	Paula Santos, Portugal	Presenter
016	Assessment of the respective role of clinical factors - institutionalisation, disease severity and disease duration - on the observed hypovitaminosis D in patients with major depression
	Raoul Belzeaux, France	Presenter
018	Neurobiology of depression: New perspectives for an old disease
	Rui Malta, Portugal	Presenter
019	A Study of Anger, Alexithymia, and Depression in Korean Patients with Functional Dyspepsia
	Sang-Yeol Lee, Korea, Republic of	Presenter
020	Effect of Tramadol on corticosteroid receptor function in patients with major depression
	Irene Minenko, Ukraine	Presenter

No.	P-44 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Childhood Adolescent Disorder
Session title:	Childhood & Adolescent Disorders III
	Martin Hatzinger, Switzerland	Chair

001	Comparisonal investigation of Rap personality disorder in youngster
	Arsalan Khanmohammadi, Iran	Presenter
002	Emotional intelligence and mental health in university students
	Arsalan Khanmohammadi, Iran	Presenter
003	Impact of schoolastic stressors on general health and achievement motivation among university students
	Arsalan Khanmohammadi, Iran	Presenter
004	Adult Attention Deficit Hyperactivity Disorder association with Synaptosomal-Associated Protein (SNAP-25) polymorphisms
	Hasan Herken, Turkey	Presenter
005	Validation of the Children’s Sleep Habits Questionnaire in a Greek sample
	Dimitrios Dikeos, Greece	Presenter
006	Children’s sleep motor phenomena: Differential diagnostics with epileptic seizures
	Elmira Sagutdinova, Russia	Presenter
007	Autism, smelling behavior and obsessive compulsive disorder: Case series
	Fulya Maner, Turkey	Presenter
008	Emotional regulation in a family context: A study in adolescent cannabis abusers and their parents
	Géraldine Dorard, France	Presenter
009	Attention deficit hyperactivity disorder among Ukrainian primary school children: Prevalence and co-morbid conditions
	Igor Martsenkovsky, Ukraine	Presenter
010	Treatment and rehabilitation of the children with autism spectrum disorders (ASD) and schizophrenia
	Inna Melakh, Ukraine	Presenter
011	Catatonia in autism and other neurodevelopmental disabilities
	Lea Elisabeth Wachtel, USA	Presenter
012	Riluzole for affective and behavioral disturbance in autism
	Lea Elisabeth Wachtel, USA	Presenter
013	The comparison of between social skills in 2 groups of children with ADHD and LD
	Mehdi Sahragard Toghchi, Iran	Presenter
014	Elective mutism: Epidemiology, clinical characteristics, dynamic
	Natalia Kirillina, Russia	Presenter
015	Cruel treatment with children in the family and correction methods
	Nataliya Zozul, Ukraine	Presenter
016	No alterations in Serum Brain Derived Neurotrophic Factor levels in Attention Deficit Hyperactivity Disorder (ADHD).
	Roberta Zanardini, Italy	Presenter
017	Sleep spindle activity in kindergarten children is associated with slow wave sleep (SWS) and coping strategies
	Thorsten Mikoteit, Switzerland	Presenter
018	Gender differences in mental health problems in early adolescence
	Umaporn Trangkasombat, Thailand	Presenter
019	Symptomatology and defense mechanisms of adults with ADHD
	Vanessa Silva, Brazil	Presenter
020	Sleep-related eating disorder and Zolpidem: An open interventional cohort study
	Yun-Kwok Wing, China, People's Republic of :	Presenter

No.	P-45 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders VII
	Rainald Mössner, Germany	Chair

001	Post-injection delirium/ sedation syndrome observed with olanzapine long-acting injection
	Angela Hill Gulliver, USA	Presenter
002	Visual scanning in schizophrenia: Effects of instructions on visual categorisation
	Céline Delerue, France	Presenter
003	Quantifying cortical thinning in first episode schizophrenia
	Christoph Schultz, Germany	Presenter
004	Effect of agonists of metabotropic glutamate receptors on schizophrenia like behavior in rats
	Karel Vales, Czech Republic	Presenter
005	Differential white matter alterations in schizophrenia: A study with DTI and tract-based spatial statistics
	Christoph Schultz, Germany	Presenter
007	Familial and sporadic schizophrenia: A comparison of somatic diseases and abuse in patients and their relatives
	Kristina Melkersson, Sweden	Presenter
008	One year outcome of first psychotic episode: Tunisian inpatients population
	Anwar Mechri, Tunisia	Presenter
009	Impact of Schizophrenia Candidate Genes on Antisaccade Task performance in a population of young men
	Nikolaos Smyrnis, Greece	Presenter
010	Larger time variability for basic decision processes in schizophrenia
	Nikolaos Smyrnis, Greece	Presenter
011	Long-term treatment with Asenapine versus Olanzapine in subjects with persistent negative symptoms of Schizophrenia
	Pilar Cazorla, USA	Presenter
012	Dose selection of asenapine: Application of mathematical models based on D2 receptor occupancy
	Rik Degreef, Netherlands	Presenter
013	Mentally Ill, Violence and Stigma
	Snezana Vladejic, Serbia and Montenegro	Presenter
014	Implicit planning of simple motor sequences in schizophrenia as measured by the Line-Sequencing Task
	Sofie Houthoofd, Belgium	Presenter
015	Psychobiology and prognosis of atypical psychosis
	Stefano Spanarello, Italy	Presenter
017	Subnanosecond fluorescence spectroscopy in the study of albumin binding sites in first - episode drug-naive patients with paranoid schizophrenia
	Yuriy Gryzunov, Russia	Presenter
018	Probabilistic classification and gambling in medicated schizophrenic patients: Comparison of olanzapine, risperidone, clozapine and typical antipsychotics
	Richard J. Beninger, Canada	Presenter

No.	P-46 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychotic Disorders
Session title:	Psychotic Disorders VIII
	Norbert Müller, Germany	Chair

001	Serum nitric oxide levels and schizophrenia: A pilot study
	Amra Memic, Bosnia and Herzegovina	Presenter
002	Oxidative stress - linked changes in patients with schizophrenia and metabolic syndrome
	Bogdan Nemes, Romania	Presenter
003	Schizophrenia deficits of interference-control processes in perception and memory
	Chara Malapani, USA	Presenter
004	The ketamine model of schizophrenia and semantic memory
	Erica Neill, Australia	Presenter
005	Episodic memory in schizophrenic patients, their biological relatives and normal people
	Gholam Ali Nikpour, Iran	Presenter
006	Neural correlates of the recognition processing of emotional words in patients with schizophrenia
	Jae-Jin Kim, Korea, Republic of	Presenter
007	Differential impairment of mesolimbic reward prediction and prediction error processing in unmedicated schizophrenics
	Jan Reuter, Germany	Presenter
008	Perinatal immune activation impairs emotional and cognitive functions with altered hippocampal glutamatergic neurotransmission in adult mice
	Kiyofumi Yamada, Japan	Presenter
009	Improvement in cognitive functioning in schizophrenia after 6-month treatment with olanzapine
	Adam Klasik, Poland	Presenter
010	Impact of cognitive functions and anxiety on the quality of life in schizophrenia
	Krzysztof Krysta, Poland	Presenter
011	Improvement of immediate and delayed recall in schizophrenia after a 6-month rehabilitation program
	Maria Veroniki Karidi, Greece	Presenter
012	Influence of psychopharmacotherapy on the aspects of secual self-perception in patients suffering from schizophrenia or depression
	Djulijano Ljubicic, Croatia	Presenter
013	Efficacy of modafinil in treating clozapine-associated sedation in patients with schizophrenia
	Nikolaos Kouroumalos, Greece	Presenter
015	Cognitive measures in healthy controls and schizophrenic probands
	Sara Pereira, Portugal	Presenter
016	Reducing stigma and discrimination against people with mental disorders
	Snezana Djordjevic, Serbia and Montenegro	Presenter
017	Synergistic impacts of DISC1 mutation and neonatal polyI: C treatment on adult phenotypes in mice: A novel mouse model of schizophrenia with gene - environment interactions
	Taku Nagai, Japan	Presenter
018	Psychopathologic changes after anticholinergic challenge in drug-free patients with schizophrenia and healthy volunteers
	Tanja Veselinovic, Germany	Presenter
019	Relationship between thyroid hormone concentrations and severity of mental symptoms in acute psychoses
	Vesta Steibliene, Lithuania	Presenter

No.	P-47 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Brain Function
Session title:	Brain Function IV
	Michael Trimble, United Kingdom	Chair

001	Efficiency and security with TMS in depressive episodes
	Beatriz Quadrelli, Uruguay	Presenter
002	Change in heart rate variability after electroconvulsive therapy in patients with major depressive disorders
	Ali Bozkurt, Turkey	Presenter
003	Reduced cortical inhibition in Japanese patients with schizophrenia under medication
	Asami Kose, Japan	Presenter
004	Repetitive transcranial magnetic stimulation: Elderly depressed-neuronavegated study
	Bianca Bellini, Brazil	Presenter
005	The influence of HF-rTMS treatment on 5-HT 2A receptor binding in medication-resistant unipolar depressed patients
	Chris Baeken, Belgium	Presenter
006	Monitoring of ECT Service in a Mental Health Trust in the UK: An audit-based report
	Guru Rao Srinivasan, United Kingdom	Presenter
007	Optimise ECT techniques: The effects of pulse width manipulation on the efficacy of ECT treatment in depression
	Harm-Pieter Spaans, Netherlands	Presenter
008	ECT efficacy: Correlations between clinical improvement, memory performance and memory complaints
	Daniel Barrocas, Portugal	Presenter
009	Influence of right frontal repetitive Transcranial Magnetic Stimulation (rTMS) on the affective picture perception
	Jacqueline Hoeppner, Germany	Presenter
010	Changes in brain activities evoked by masked traumatic stimuli in patients with Posttraumatic Stress Disorder (PTSD): A functional MRI study
	Jeong-Ho Chae, Korea, Republic of	Presenter
011	The effect of repetitive transcranial magnetic stimulation (rTMS) on fear extinction in rats
	Jeong-Ho Chae, Korea, Republic of	Presenter
012	From psychopathology to psychosurgery - leaving the localisationist rationale behind?
	Lara Rzesnitzek, Germany	Presenter
013	Instantaneous and complete suppression of motor tics and obsession and compulsions with unilateral thalamic deep brain stimulation in Tourette - Syndrome
	Lara Rzesnitzek, Germany	Presenter
014	Repetitive transcranial magnetic stimulation postpartum depression treatment neurocognitive and behavioral symptomatology therapeutic effects
	Martin Myczkowski, Brazil	Presenter
015	Predictors of response to electroconvulsive therapy obtained using the three - factor structures of the Montgomery and Åsberg Depression Rating Scale for major depressive disorders in Japanese patients
	Mioto Okazaki, Japan	Presenter
016	Abnormalities in cortical and trans-callosal inhibitory mechanisms in subjects at high-risk for alcohol dependence: A TMS study
	Muralidharan Kesavan, India	Presenter
017	Effect of augmentative repetitive transcranial magnetic stimulation in resistant obsessive - compulsive disorder: A preliminary study
	Sunil Mittal, India	Presenter
018	Transcranial direct current stimulation (tDCS) in therapy - resistant depression: A double-blind, placebo - controlled study
	Ulrich Palm, Germany	Presenter
019	The use of transcranial laser stimulation for treating developmental language deficits in the preschool period
	Victor Sevastyanov, Russia	Presenter

No.	P-48 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Psychopharmacology/ Antipsychotics III
	Noppamars Wongwitdecha, Thailand	Chair

001	Reasons for olanzapine discontinuation in Japanese patients with schizophrenia.－ Comparison with the results of CATIE －
	Akihisa Akahane, Japan	Presenter
002	Evaluating clozapine dose - response relationship using EEG monitoring
	Amresh Shrivastava, Canada	Presenter
003	Does Neuroendocrine offer an outcome predictive indicator: Experience of Serum Prolactin in 5 year outcome in first episode drug naive patients
	Amresh Shrivastava, Canada	Presenter
004	Does Serum Prolactin elevation & Prolactin related side effects of atypical antipsychotics represent a Prolactin-Dopamine subgroup in schizophrenia
	Amresh Shrivastava, Canada	Presenter
006	Tolerability, safety and treatment response of flexible doses of paliperidone ER in recently diagnosed patients with schizophrenia
	Andreas Schreiner, Germany	Presenter
007	Long-term remission in schizophrenia and schizoaffective disorder: Results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE)
	Andreas Schreiner, Germany	Presenter
008	Atypical neuroleptic risperidone modulates astroglial functions
	Carmem Gottfried, Brazil	Presenter
009	Differential effects of olanzapine, risperidone and haloperidol on serum brain - derived neurotrophic factor levels and psychopathological variables in chronic schizophrenic patients
	Emmanouil Rizos, Greece	Presenter
010	Skill proceduralization in schizophrenia - the differential effect of typical and atypical neuroleptics
	Emmanuelle Pourcher, Canada	Presenter
011	5-HT2A receptor occupancy in first episode schizophrenia patients treated with quetiapine
	Hans Rasmussen, Denmark	Presenter
012	The metabolism of chlorpromazine by human cytochrome P450 isoenzymes - a comparison with other phenothiazines
	Jacek Wójcikowski, Poland	Presenter
013	Asenapine improves a subchronic phencyclidine-induced deficit in object recognition memory in the rat
	Jo Neill, United Kingdom	Presenter
014	The effects and characteristics of high-dose Quetiapine (equal/higher than 800mg/day) use
	Jeung-Gee Kim, Korea, Republic of	Presenter
015	Interaction of Aripiprazole with Citalopram and MDMA: Potential role of SEROTONIN 5-HT2B receptor antagonism
	Marie-Bernadette Assie, France	Presenter
017	Effects of olanzapine on visual recognition memory in mice
	Oguz Mutlu, Turkey	Presenter
018	The use of atypical antipsychotics in patients with substance-related disorders and posttraumatic stress disorder and their self-perception of quality of life
	Slaven Zudenigo, Croatia	Presenter
019	CIPS: A naturalistic study of Consta in Polynesian subjects
	Sylvester Wayne Miles, New Zealand	Presenter
020	Risk factors of aripiprazole treatment discontinuation in japanese schizophrenia patients
	Yoshiteru Takekita, Japan	Presenter

No.	P-49 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Psychopharmacology
Session title:	Psychopharmacology III
	Alessandro Serretti, Italy	Chair

001	Prevalence of drug induce psychosis among amphetamine and methamphetamine dependence patients
	Ahmad Hatim Sulaiman, Malaysia	Presenter
002	Safety and efficacy of aripiprazole in the treatment of amphetamine and methamphetamine induce psychosis: A preliminary results
	Ahmad Hatim Sulaiman, Malaysia	Presenter
003	Aripiprazole’s intrinsic activity is not enhanced on striatal membranes of rat chronically pre-treated with haloperidol
	Beryl Koener, Belgium	Presenter
004	Comparative evaluation of the predictors that diferentiate Valproate’s effect in the long-term treatment of Bipolar Disorders (BD)
	Fatime Elezi, Albania	Presenter
005	Efficacy comparison of Lamotrigine versus Lithium Carbonate in Bipolar Disorder II (BP II) patients treated for the first time with mood stabilizer
	Anila Kazaferi, Albania	Presenter
006	Evaluation of anxiolytic properties of the diethyl ether extract of Gentiana kochiana
	Gordana Tovilovic, Serbia and Montenegro	Presenter
007	Long-term efficacy and saftey of galantamine in outpatients with mild cognitive disorder
	Julio Zarra, Argentina	Presenter
008	Mild cognitive disorder and depression: Treatment with association between Galantamine and Escitalopram
	Julio Zarra, Argentina	Presenter
009	Therapy of addition for Alzheimer's disease: Combination with Galatamine and Memantine
	Julio Zarra, Argentina	Presenter
010	Limited anti-apoptotic activity of valproic acid on leukemic cell line
	Krzysztof Pietruczuk, Poland	Presenter
011	New perspectives: Atypical anxiolytics block the development of ethanol -and benzodiazepine withdrawal-induced anxiety in experiment
	Larisa Kolik, Russia	Presenter
012	Anxiety disorders in primary care: Effects of anxiolytic treatments on cognitive functions, a French naturalistic study
	Fadwa Cazala, France	Presenter
013	Pentoxifylline Ameliorates Methamphetamine - induced cognitive deficits
	Ming-Huan Chan, Taiwan	Presenter
014	Yokukansan supresses methamphetamine-induced hyperlocomotion in mice
	Naoki Uchida, Japan	Presenter
015	5 - HT2C receptor activation inhibits stress - induced increase in 5 - HT transmission: Relevance of receptor desensitization to the anxiolytic effect of chronic parocentine in mice
	Laurence Lanfumey, France	Presenter
019	Management alopecia induced by mood stabilizers
	Susana Mendes, Portugal	Presenter
020	Translocation of sigma 1 receptors from the cytoplasm to vicinity of the plasma membrane in response to Afobazol treatment
	Tatyana Antipova, Russia	Presenter

No.	P-50 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Other
Session title:	Other/ Obsessive-Compulsive Disorders/ Personality Disorders
	Martin Aigner, Austria	Chair

001	Checking behaviours in obsessive-compulsive disorder don’t compensate for working memory deficits
	Luc Mallet, France	Presenter
002	Piercing/ Tattoo and underlying psychopathologies
	Antonio D´Ambrosio, Italy	Presenter
003	Morningness - eveningness personality traits and melatonin levels
	Armando Morera, Spain	Presenter
004	Headache perception in the mental illness
	Evangelos Neroutsos, Greece	Presenter
005	Munchhausen syndrome
	Evangelos Neroutsos, Greece	Presenter
006	Psychosis and stroke
	Evangelos Neroutsos, Greece	Presenter
007	Serotonin reuptake inhibitors unresponsiveness, hormonal endophenotypes and serotonergic polymorphisms in obsessive compulsive disorder
	Fábio Corregiari, Brazil	Presenter
008	Riskful decision making and delayed discounting procedure in patients with antisocial and borderline personality disorder
	Farhad Faridhosseini, Iran	Presenter
009	Comorbid axis II and axis I disorders in psychiatric inpatients in western Quebec
	Florina Cealicu Toma, Canada	Presenter
010	Obsessive-compulsive disorder and exhibitionism. Due to a clinical case
	Jose Manuel Lopez Santin, Spain	Presenter
011	Adding pregabalin to a patient with obsessive compulsive disorder resistant to Selective Serotonin Reuptake Inhibitors (SSRIS). A case study
	Konstantinos Papanikolaou, Greece	Presenter
012	Psychogenic polydipsia. A case report
	Konstantinos Papanikolaou, Greece	Presenter
013	Treatment of tourette's disorder in an adolescent with the administration of aripiprazole. A case study
	Konstantinos Papanikolaou, Greece	Presenter
014	"Been there, done that": Scent marking behavior in the rabbit as a possible model for understanding the neural control of stereotyped and repetitive behavioral patterns
	Kurt Hoffman, Mexico	Presenter
015	The neuropharmacology of "just right": Nest building behaviour as a possible model for understanding the pathophysiology of obsessive compulsive disorder (OCD)
	Kurt Hoffman, Mexico	Presenter
016	The comparison of defense style and mental disorder between military students and unmilitary students
	Leila Heydarinasab, Iran	Presenter
017	Clinical characteristics of obsessive compulsive disorder with Schizophrenia
	Min-Seong Koo, Korea, Republic of	Presenter
018	Non-verbal memory dysfunction in checking type obsessive-compulsive disorder
	Min-Seong Koo, Korea, Republic of	Presenter
020	An examination of delusional thinking in Body Dysmorphic Disorder
	Susan Rossell, Australia	Presenter
021	Correlation relationships between steroid and thyroid hormones and motivational features in patients with neurotic, stress-related and somatoform disorders
	Valentin Semke, Russia	Presenter
022	Cannabinoid CB2 receptor mediated regulation of impulsive - like behaviors in mice
	Francisco Navarrete, Spain	Presenter

No.	P-51 - Poster Presentation
Time:	12.30-14.00
Room:	Foyer
Topic:	Other
Session title:	Other II
	Olya Mikova, Bulgaria	Chair

001	The aggressive and potentially patient
	Birgul Özkan, Turkey	Presenter
002	Neurobiology of aggression
	Margarita Blanco Prieto, Spain	Presenter
003	The dynamics of violent and non-violent mortality as indicator of societal crisis
	Dmitry Veltishchev, Russia	Presenter
004	KINA in psychoneuroimmunology
	Enrique Galli, Peru	Presenter
005	Karolinska Interpersonal Violence rating, a new tool in biological psychiatric research
	Jussi Jokinen, Sweden	Presenter
006	Kleine - Levin Syndrome and Neuroleptic Malignant Syndrome
	Beata Havaki-Kontaxaki, Greece	Presenter
007	Behavioural analysis of sexuality in relation to HIV/AIDS: Commitment in sexual behaviour
	Pramod Shankpal, India	Presenter
008	Combating psycho-social stigma & discrimination associated with sexual disorders: Efforts by faith based community model of Indian NGO
	Pramod Shankpal, India	Presenter
009	Homicide and roots of homicidal behavior
	Dragana Arandjelovic, Serbia and Montenegro	Presenter
010	Sleep and circadian disturbances in depression
	Predrag Misic, Serbia and Montenegro	Presenter
011	Treatment of bipolar disorders
	Vesna Todorovic, Serbia and Montenegro	Presenter
012	Burnout-related emotional and physical exhaustion, but not depressive symptoms, is related to sleep complaints in a non-clinical sample
	Edith Holsboer-Trachsler, Switzerland	Presenter
013	Polysomnographic profiles of patients suffering from restless legs syndrome, depressive symptoms, and major depression are not gender-related
	Johannes Beck, Switzerland	Presenter
014	REM-sleep increases transfer of executive knowledge after metacognitive learning
	Serge Brand, Switzerland	Presenter
016	The use of neuropsychopharmacs in forensic patients and their self-esteem and self-perception of quality of life
	Suzana Jonovska, Croatia	Presenter
017	The use of psychopharmacs in schizophrenic patients with and without committed criminal offence
	Suzana Jonovska, Croatia	Presenter
018	“Oh, Baby, please don’t cry!” Cortisol secretion in infants suffering from infantile colic is related to sleep, crying duration, and to family strain and depressive symptoms in mothers
	Serge Brand, Switzerland	Presenter
019	Children suffering from separation anxiety disorders (SAD) show increased HPA axis activity compared to healthy controls
	Edith Holsboer-Trachsler, Switzerland	Presenter
020	Experience in long-term meditation reduces the hypothalamic-pituitary-adrenocortical (HPA) axis activity
	Serge Brand, Switzerland	Presenter
021	Long-term treatment of Restless Legs syndrome does not improve satisfaction with life and sleep compared to healthy controls
	Johannes Beck, Switzerland	Presenter
022	Anxiety and aggression - contradiction or transmission and reciprocity? Personal and family level
	Dusan Lazarevic, Serbia and Montenegro	Presenter

No.	TG-10 - WFSBP Treatment Guidelines
Time:	14.00-15.30
Room:	Room 242A
Topic:	Neurodegenerative Disorders
Session title:	Dementia
	Masatoshi Takeda, Japan	Chair

	Ralf Ihl, Germany	Presenter
	Serge Gauthier, Canada	Presenter

No.	D-10 - Debate
Time:	14.00-15.30
Room:	Room 351
Topic:	Genetics
Session title:	Is pharmacogenetics ready for clinical application
	Nicole Praschak-Rieder, Austria	Chair

	Min-Soo Lee, Korea, Republic of	Proponent
	Alessandro Serretti, Italy	Opponent

No.	W-13 - Workshop
Time:	14.00-15.30
Room:	Room 251
Topic:	Psychopharmacology
Session title:	Drugs, hormones and psychoneuroimmunoendocrinology
	Raquel Teresa Zamora-Cabral, Uruguay	Chair

001	Stress, the immune system and depression
	Brian E. Leonard, Ireland	Speaker
002	Psychopharmacology on the feminine vital cycle
	Liliana Rendon, Paraguay	Speaker
003	Psychiatric effects of hormones
	Andrea Lopez Mato, Argentina	Speaker
004	Hormonal Effects of Psychiatric Drugs
	Raquel Teresa Zamora-Cabral, Uruguay	Speaker

No.	W-14 - Workshop
Time:	14.00-15.30
Room:	Room 242B
Topic:	Brain Function
Session title:	Prefrontal cortex-relevance in psychiatry
	E. Mohandas, India	Chair

001	Prefrontal cortex - functional neuroanatomy
	E. Mohandas, India	Speaker
002	Prefrontal cortex - relevance to psychiatric disorders
	Venkat Subramaniam, India	Speaker

No.	S-86 - Symposium
Time:	14.00-15.30
Room:	Blue Amphitheatre
Topic:	Brain Function
Track:	1 Basic
Session title:	Neural circuitry and mood disorders: Relationship to course of illness and treatment outcome
	Russell Joffe, USA	Chair
	Thomas Frodl, Germany	Co-Chair

001	Neural circuitry in depression: Concepts and rationale
	Russell Joffe, USA	Speaker
002	Hippocampal volumes predict remission rates early in the course of depression
	Glenda MacQueen, Canada	Speaker
003	Has depression-related decline of brain morphology an impact on illness course?
	Thomas Frodl, Germany	Speaker
004	Towards the development of neurobiological predictors of treatment response: Studies in neuroimaging
	Cynthia Fu, United Kingdom	Speaker

No.	S-87 - Symposium
Time:	14.00-15.30
Room:	Salle Maillot
Topic:	Affective Disorders (Bipolar)
Track:	3 Interface
Session title:	Clinical and biological correlates of outcome prediction in major psychoses
	Carlo Altamura, Italy	Chair
	Trevor Young, Canada	Co-Chair

001	Bipolar disorder
	Trevor Young, Canada	Speaker
002	Neuromorphology and outcome prediction
	Philip McGuire, France	Speaker
003	Psychoimmunology and drug response
	Norbert Müller, Germany	Speaker
004	Duration of untreated psychosis: is it a criterion for outcome prediction?
	Carlo Altamura, Italy	Speaker

No.	S-88 - Symposium
Time:	14.00-15.30
Room:	Room 352AB
Topic:	Anxiety
Track:	1 Basic
Session title:	Recent advances in neuropharmacology of stress
	Noppamars Wongwitdecha, Thailand	Chair
	Mitsuhiro Yoshioka, Japan	Co-Chair

001	Early life stress modifies the effects of 5-HT1A agonist, 8-OH-DPAT in animal tests of anxiety and depression
	Noppamars Wongwitdecha, Thailand	Speaker
002	Early postnatal stress disturbs normal development of the serotonergic neurons in the raphe nuclei
	Mitsuhiro Yoshioka, Japan	Speaker
003	Pros and cons of stress on the development of social behavior
	Shun Nakamura, Japan	Speaker
004	Behavior recognition technology application in neuropharmacology of stress
	Yiqing Liang, USA	Speaker

No.	S-89 - Symposium
Time:	14.00-15.30
Room:	Room 252B
Topic:	Psychotic Disorders
Track:	1 Basic
Session title:	New insights into abnormal neural oscillations in schizophrenia and the structural and receptor basis of the abnormal neural circuitry
	Robert McCarley, USA	Chair
	Toshiaki Onitsuka, Japan	Co-Chair

001	Gamma band and MRI structural abnormalities in first episode schizophrenia and mania
	Robert McCarley, USA	Speaker
002	Abnormal neural oscillatory activity to speech sounds in schizophrenia: An MEG study
	Toshiaki Onitsuka, Japan	Speaker
003	High-frequency oscillations during perceptual organisation in first-episode and chronic schizophrenia
	Peter Uhlhaas, Germany	Speaker
004	N-methyl-D-aspartic acid receptor antagonist induced frequency oscillations in mice recreates pattern of electrophysiological deficits in schizophrenia
	Steven Siegel, USA	Speaker

« previous day

Thursday, 2. July 2009